SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " imbalance " 32 found 🔀 AI-powered Shuffle
Antidepressants don't fix a chemical imbalance, so what do they do?
Antidepressants do more than alter serotonin. Scientists are exploring how these drugs change emotional processing, brain plasticity, and recovery.
Maxine Peake Joins BAFTA-Qualifying Short The Secret Assistants
Maxine Peake joins Katey Lee Carson’s The Secret Assistants as EP on a film about a newcomer confronting power imbalances in the movie business.
Antidepressants Don’t Correct A Chemical Imbalance. How, Then, Do They Work?
Here’s how psychiatrists like me think about the most promising hypotheses.
The Math Singularity Is Here, and Science May Be Next
OpenAI has released an extraordinary body of mathematical work produced by an unreleased frontier model: 722 manuscripts spanning 372 research families across fields including number theory, complexity theory, and mathematical physics. Each result required, on average, the equivalent of roughly three hours of ChatGPT Pro reasoning. A New Era of Discovery We may be witnessing the beginnings of a “math singularity”: a point at which machine-generated discovery accelerates beyond humanity’s ability to independently reproduce, verify, or fully absorb it. If frontier models can generate hundreds of meaningful results in the time it takes a human researcher to investigate one, the constraint will no longer be producing new mathematics. It will be our capacity to validate, interpret, and integrate it. This does not make mathematicians obsolete. It changes their role. They may increasingly serve as guides, critics, and meaning-makers. Increasingly, they will decide which questions matter, determining which results can be trusted, and explaining why they are important. Mathematical insight may become abundant, while human judgment becomes more valuable than ever. Mathematics May Be Only the Beginning Every scientific discipline could eventually experience a similar acceleration. AI systems could generate and test hypotheses, connect findings across specialized fields, and explore possibilities at a scale no human research community could match. In medicine, imagine models identifying overlooked disease mechanisms, designing drugs and clinical trials, personalizing treatments, or discovering cures in months rather than decades. In materials science, AI could help create better batteries and cleaner industrial processes. In climate science, it could accelerate advances in energy, forecasting, and carbon removal. In biology, it could uncover relationships hidden across enormous genomic and molecular datasets. The result would not simply be faster research. It could expand the frontier of what is scientifically possible. The New Bottleneck Scientific discovery, however, is not the same as scientific progress. A medical breakthrough must still survive laboratory testing, clinical trials, regulatory scrutiny, manufacturing constraints, and real-world deployment. As machine-generated ideas multiply, the bottleneck may shift from producing breakthroughs to validating them safely and translating them into practice. We may soon have more hypotheses than laboratories can test, more drugs than clinical trials can evaluate, and more mathematical results than experts can review. That imbalance will require better systems for automated verification, reproducible research, prioritization, peer review, and collaboration between AI and domain experts. The importance of OpenAI’s work is not merely the number of manuscripts produced. It offers a glimpse of a world in which intelligence can explore thousands of intellectual paths in parallel. If ideas cease to be scarce, humanity’s defining challenge will be deciding which are true, which matter, and how to turn them into progress. The math singularity is not the end of human inquiry. It is the beginning of a new kind—one in which machines expand the frontier of knowledge and humans decide where it should lead. Subscribe Share Leave a comment
Opinion: UChicago’s growing gender imbalance deserves answers
A former UChicago admissions officer questions why the university is enrolling more male students when substantially more female students applied.
A 'decent start' or are Liverpool 'underperforming'?
Defence looks sharp with the new additions, the middle looks imbalanced as we persist with Florian Wirtz. Gareth: Let's face it, we were spoiled in Arne Slot's first season. Iraola is still finding out about players and who will fit into his style of play.
Political boot camps for women could redress gender imbalance
Immersive boot camps for women could be a way to overcome the stark gender imbalance in political leadership, according to new research that examined how to increase the political ambitions of talented ...
Big-money donations poison British politics. We can stop the mega-rich buying access and influence
I’ve seen how imbalances in campaign spending can distort democracy. The multi-million-pound gifts to Reform must act as a final wake-up call, says former UK prime minister Gordon Brown
Trump says he's lifting 10% tariff on Irish whiskey because 'everybody's been bugging me'
President Donald Trump announced in April that he was lifting certain tariffs on U.K. whiskey, which includes Scotch and spirits made in Northern Ireland, creating an imbalance with Ireland.
Bone Health Without the Hype
I am at the Australasian Menopause Society meeting and we had a fantastic lecture on Bone Health on Day 2, called, “Everything you need to know about bones - except the boring bits!” Spoiler alert, there were no boring bits. The lecture was given by Dr. Amanda Beech, who is a senior staff specialist in Obstetric Medicine and Endocrinology at the Royal Hospital for Women, where she is director of the Bone Density Unit. I want to summarize my top 10 take-aways for you. Share Osteoporosis is a disease of low bone mass, disruption of bone microarchitecture, and fragility of the skeleton. It is a silent disease…until someone develops a fracture. The diagnosis of osteoporosis is based on either fragility/minimal trauma fractures or a T-score of less than -2.5 on a DXA (Dual-Energy X-ray Absorptiometry) or bone scan. It is important to recognize that about 50% of minimal trauma fractures occur when women have low bone mass (often referred to as osteopenia), but not osteoporosis. This tells us that bone strength is more complicated than a number on a DXA report. I am going to add a little here that wasn’t in the talk (one can only include so much in 25 minutes), as many women might read the above paragraph and think, “Shouldn’t we be treating everyone with low bone mass if this is when 50% of the fractures occur?” Many fractures happen for women with low bone mass because there are so many women with low bone mass –it is a statement about the population on a whole, not about the fracture risk of low bone mass. For you as an individual, bone density is only one component of fracture risk and many women with lower bone mass will not have a significantly elevated fracture risk. This is why individualized risk assessment matters. Subscribe We build bone in our teens and twenties, and by the time we are about thirty we have reached peak bone mass. This is why, when we discuss risk factors for osteoporosis, it is important to consider factors that might have affected us in our teens and twenties when we were actively building bone, such as nutritional restriction/energy imbalance. It is important to ask women about a history of eating disorders, and for those with such a history, getting a bone scan in perimenopause or at age 50 is likely warranted. (This image below isn’t from the talk, but is similar to one that was). Bone mass is relatively stable until about two years before the final menstrual period, and perimenopause marks a time of rapid bone loss for women. Using urinary markers of bone loss we know that the time of significantly accelerated bone loss starts about 1 year before the final period and ends about 2 years after the final period. The Study of Women’s Health Across the Nation (SWAN) shows that over the menopause transition women lose an average of 10.6% of the bone at their lumbar spine and 9.1% at the femoral neck While this wasn’t covered in the lecture, I want to add that the rapid bone loss during perimenopause is clearly related to more than estradiol, because during this time estradiol levels can be erratic and not uniformly low. Bone loss during perimenopause is likely a multi-hormone event. For example, rising FSH (follicle stimulating hormone) tracks with bone loss better than estradiol, and there is evidence that FSH may act directly on bone. While decreased estrogen matters, there is clearly more going on. FSH and bone is an active area of research. Subscribe Screening for osteoporosis was recommended fairly broadly before age 65, and was taken from the “Practitioner’s Toolkit for Managing Menopause,” from Monash University. Here is a screenshot from the toolkit that was used as a slide: I am going to add a little bit more about body weight here for clarification. Low body mass (typically 152.1 lb): 0 points (risk neutral) 60–69 kg (132.3–152.1 lb): 3 points (adds some risk)
Elix Brings 5,000 Years Of Chinese Medicine To Modern Women’s Health
Elix founder Lulu Ge brings 5,000 years of Chinese medicine into personalized herbal formulas—helping women treat hormonal imbalance symptoms.
The new "science golden age" looks suspiciously like a grift
This edition of PN is made possible by paid subscribers. Become one ⬇️ 🚀 Subscribe to PN 🚀 The Trump regime is trying to usher in a “Golden Age in Science” where scientific research is run like a Trump family business, artificial intelligence is all that matters, profit is everything, and expertise is for chumps. Or at least that’s the vision emerging from a new 123-page “Report to the President” from Michael Kratsios, the Director of the White House Office of Science and Technology Policy. In a normal administration, you could probably skip over learning about a science policy document — but this is no normal administration, and this is no normal science policy document. Instead, it’s Trump’s attempt to end the actual golden age of science that was kicked off in 1945 with the publication of '“The Endless Frontier” by Vannevar Bush. [ ](https://www.publicnotice.co/p/harmeet-dhillon-portland) [ Harmeet Dhillon demonstrates danger of posting through it ](https://www.publicnotice.co/p/harmeet-dhillon-portland) Liz Dye · Jul 29 [ Read full story ](https://www.publicnotice.co/p/harmeet-dhillon-portland) Bush, at President Franklin Delano Roosevelt’s request, laid out a vision of federal support for science that centered on funding universities to do basic research, saying that as long as those institutions were “vigorous and healthy and their scientists are free to pursue the truth wherever it may lead, there will be a flow of new scientific knowledge to those who can apply it to practical problems in Government, in industry, or elsewhere.” Kratsios’s report is supposed to be the successor to Bush’s, and even apes the format, but this isn’t really a document about science policy. It’s one about ending science research as we know it in favor of shoveling cash at big tech companies. While it might be temping to wave this away as an aspirational policy document, Trump has already begun to shift billions in research funds to AI projects and has taken a hatchet to science funding across the board. He’s teed up the shift Kratsios proposes here, and since neither Congress nor the Supreme Court seem inclined to stop him from doing whatever he wants with taxpayer money, it isn’t doomering or hyperbole to say we are staring down the barrel of a world where the only “science” the government intends to support is for-profit tech and defense advancements. Science for dummies Part of how you can tell this isn’t a document about science is that you are immediately faced with an absolute wall of business-speak of the worst sort. Did you know we must “tightly couple our science and technology enterprises to ensure that groundbreaking ideas invented in the United States are rapidly prototyped, tested, manufactured, and scaled domestically”? You do now! That tone isn’t surprising, because Kratsios has no background in science or research. He has a bachelor’s in political science and spent most of his career working for Peter Thiel at Thiel Capital. After a stint in the first Trump administration as Chief Technology Officer, where he also did not do any science, Kratsios was tasked in 2020 with overseeing the Pentagon’s research budget for a brief time, a position that, as the Wall Street Journal put it, “carries a great deal of power in terms of dictating investment allocations.” He spent the Biden years at Scale AI as “head of strategy,” which you will also note is neither a science nor a research job. But Scale AI has contracts with the Department of Defense and, as the Washington Post wrote in 2023, “has been aggressively pitching itself as the company that will help the US military in its existential battle with China.” And now you have the necessary background for our new golden age, which is going to be a golden age of taking money away from scientists and universities and giving it to companies like Scale AI. A note from Aaron: Working with brilliant contributors like Lisa takes resources. If you aren’t already a paid subscriber, please become one to support our work. 👇 Subscribe In a genuinely galling move, Katsios spends a lot of time slamming universities because of “administrative burdens on researchers” and the “well-documented inefficiencies” in academia, the message being that those damn universities waste the time of amazing researchers with paperwork. Except it’s the administration that is attempting to impose inefficient, unnecessary burdens on those researchers with a proposed Office of Management and Budget rule that would require senior political appointees to approve every science grant and ensure it aligns with Trump’s personal priorities. Researchers would also have to seek prior government approval to attend conferences or publicize their research. And political appointees could terminate any grant at any time if they feel like it. [ ](https://www.publicnotice.co/p/omb-rule-science-funding) [ The murder of expertise ](https://www.publicnotice.co/p/omb-rule-science-funding) Lisa Needham · Jun 11 [ Read full story ](https://www.publicnotice.co/p/omb-rule-science-funding) But when it comes to AI, we’re going to “restore permissionless innovation.” The report proposes to give lucky ducky innovators a pile of cash up front for grants lasting five years or longer, saying “awards should be fully-funded in year one, with all resources earmarked upfront, to minimize administrative burdens and reduce pressure for researchers to generate intermediate results to secure continued funding.” Yeah, wouldn’t want to have to make the Very Special Tech Bros show results or get money parceled out year by year like the plebes at universities. The report also proposes that we should have “fast grants” with “simplified applications requiring just a few pages of writing” because that is definitely how science works, just writing a bit off the dome and getting some cash. [ ](https://www.publicnotice.co/p/trump-ai-action-plan-altman-llms) [ Tech elites are turning AI into ChatGPTrump ](https://www.publicnotice.co/p/trump-ai-action-plan-altman-llms) Paul Waldman · July 29, 2025 [ Read full story ](https://www.publicnotice.co/p/trump-ai-action-plan-altman-llms) Oh, and we should have prizes and challenges, where multiple teams compete. The proposed prizes include incentives like “advance procurement commitments,” which means the federal government agrees to buy whatever is being developed. There’s also “regulatory fast-tracking,” making sure all those great AI thingies don’t have to wait too long to be unleashed on a market. These aren’t incentives to do science. These are incentives to develop things with tax dollars that you can then sell to the government for more tax dollars. In the suggestion that might be the most unhinged, the most very opposite of how both government and research work, our new age will include “golden tickets.” That’s where an individual reviewer in an agency — yes, just one person — can “recommend unconventional proposals that may not pass consensus-driven review panels” because somehow this will “surface valuable ideas too divisive for committees and attract higher quality reviewers by empowering them to exercise independent scientific judgment.” Yes, that’s saying that a random person in an agency should be able to shovel money at some idea even if it can’t pass a review panel, and that the opportunity to do so will attract better employees because apparently all the best minds in science are chomping at the bit to be allowed to unilaterally fund AI research based on their personal vibes. But that isn’t at all how actual science works, and actual scientists aren’t unhappy about review panels. They work collaboratively, not siloed in some secret race to create the next AI chatbot. A 2020 study by the National Bureau of Economic Research examined whether peer review panels succeed in helping agencies predict which research ideas will best advance science. Peer review was better at finding “diamond in the rough” applicants than a single government program official. How about that. Trump always wants a taste It’s painfully clear that what Katsios is trying to do here is turn the whole of government science research and funding into the sort of “move fast and break things” paradigm that is the hallmark of big tech. That method works to line the pockets of tech executives, but it isn’t science. There’s a reason the government funds different kinds of research than private tech companies do. What Katsios either fails to understand or deliberately ignores is that the federal government is the main funder of basic research precisely because it can take a long time for it to bear fruit and is not intended to be profitable as such. “Basic” here does not mean rudimentary or simple, but rather research that is designed to advance scientific knowledge instead of achieving a specific outcome or product. Big tech companies don’t widely fund that sort of research, because it doesn’t make them money. Industry dollars account for only about 20 percent of basic research funding, while the government contributes around 60 percent. Big tech companies and startups do, however, rely on and benefit from that basic research. A 2019 study found that 35 percent of all patents obtained by venture-backed startups from 1976 to 2016 cited federally supported research. Basic research funded by the NIH contributed to every single drug the FDA approved from 2010 to 2016. [ ](https://www.publicnotice.co/p/trump-saudi-nuclear-deal) [ The Saudi nuclear farce and governance by whim and meme ](https://www.publicnotice.co/p/trump-saudi-nuclear-deal) Noah Berlatsky · Jul 27 [ Read full story ](https://www.publicnotice.co/p/trump-saudi-nuclear-deal) Unlike inventing the next ChatGPT, actual science is slow and iterative. Government funding of research that, on its face, would not appear to lead to any big new invention is actually what underpins those big new inventions. If the government hadn’t funded research into desert lizard venom, we wouldn’t know about semaglutide, and we wouldn’t have Ozempic. If research scientists hadn’t studied how bees optimize nectar foraging within a colony, we wouldn’t have the algorithm that assigns internet traffic across computer servers. The report assiduously ignores that a symbiotic, profitable relationship between the federal government, universities, and private companies already exists. Each federal research dollar generates about $1.50 to $3.00 in long-term economic benefits. The $36 billion the government awarded in NIH research funding in fiscal year 2025 generated $94 billion in new economic activity. Trump’s proposed new golden age is intended to strip those billions from universities, resulting in the dismantling of departments and the shuttering of labs. But Katsios has a plan for that: Universities should just become trade schools to churn out no-show STEM degrees! “Require universities and community colleges to embed practical technical training and externships into STEM curricula. Let hands-on experience and industry credentials count toward degrees.” It’s quite the feat to, on the one hand, strip schools of funding for scientific research while simultaneously demanding to control what is taught and, oh, also, colleges need to give degrees to employees at big tech companies just for being employees at big tech companies. The new golden age would also exacerbate the brain drain Trump’s policies have already caused. Nature found that in the first quarter of 2025, US scientists submitted 32 percent more job applications abroad than in 2024. A March 2025 poll by Nature of roughly 1,600 scientists found that over 1,200 said they were considering leaving the country. Europe is investing $565 million to make it a “magnet for researchers” and provide funding for scientists who relocate. The new golden age is also about embedding Trump’s xenophobia into the fabric of American science. The report complains of an “over-reliance on foreign students” that “creates a security challenge our institutions are ill-equipped to address” and that a “reliance on foreign talent sidelines American students.” This is, to put it mildly, nonsense. International students pay far higher tuition and often receive no financial aid. Their tuition dollars are what make it possible for American students to get financial aid. In the 2023-2024 school year alone, international students contributed $43.8 billion to the US economy and supported over 378,000 jobs. Those 1.1 million international students accounted for only six percent of the total number of students in higher education that year, but were such an economic engine that for every three international students, one job was created or supported. It’s impossible not to wonder whether part of Trump’s loathing for universities and their leading role in scientific research is that there is no way for him to corrupt the process and make money off it in the same way he can by giving millions and billions to Silicon Valley types who, in turn, give him millions in cash. There’s no way for his children to invest in universities that the government then gives no-bid contracts to, fattening the family’s bottom line, which is pretty much the Trump sons’ current venture capital practice. Trump and Katsios’s view of science is narrow, cramped, and wrong. We’re not in a crisis, we’re not a failed state. We’ve been a science superpower for decades, and the only thing that threatens that is Donald Trump. Tech bros are already living high off the hog in this administration. They don’t need any more of our tax dollars. Hopefully this new golden age never comes to pass. Thanks for reading Public Notice. This post is public so feel free to share it. Share We’ll be back with more tomorrow. If you appreciate today’s PN, please do your part to keep us free by signing up for a paid subscription. 🚀 Subscribe to PN 🚀 Thanks for reading, and for your support.
Business People
Mikel Dashtipour has joined Renal Specialists of Northwest Arkansas, where he provides care for patients with kidney disease, including those with chronic and end-stage kidney disease, electrolyte imbalances, fluid overload and other related conditions, and those receiving dialysis.
Business People
Mikel Dashtipour has joined Renal Specialists of Northwest Arkansas, where he provides care for patients with kidney disease, including those with chronic and end-stage kidney disease, electrolyte imbalances, fluid overload and other related conditions, and those receiving dialysis.
Alex Rodriguez Bashes Competitive Imbalance: ‘The American League Stinks'
Alex Rodriguez didn't hold back on his criticism of the Boston Red Sox and the American League.
Elections to top science bodies test Croatia’s gender equality in research
Croatia’s track-record on gender equality in science has been both questioned and lauded in recent months, following both bad and good news on the topic. On the one hand, a senior awards committee was announced without a single woman researcher included. On the other, the national science academy welcomed its first cohort of fellows with more women than men.Members of the committee, which gives national awards recognising scientific achievement, are proposed by the ministry of science and endorsed by the parliament. The current line-up does include a woman, but she is culture minister Nina Obuljen Koržinek rather than a researcher. Even then, she didn’t make it into the photograph released to announce the appointments on April 16. “The image speaks a thousand words,” says Tanja Rudež, a science journalist for Jutarnji List newspaper. “I am surprised that none of these men, all well-known scientists, saw a problem with the fact that there was not a single successful female scientist on the committee,” she told Science|Business.Ivan Đikić, a prominent Croatian biochemist based at Goethe University Medical School, commented on LinkedIn that the news illustrated a “sad truth” about the state of science in Croatia.“It [. . .] reveals a system where women, despite contributing a substantial share of high-quality, internationally competitive science, are systematically excluded from the very processes that determine recognition and influence,” he wrote. Some 60% of researchers in Croatia are women, according to the Croatian Bureau of Statistics, and they perform well in international competitions. For example, of the 12 European Research Council (ERC) grants awarded to Croatian researchers, seven went to women.“So how is it possible that decision-making bodies are still dominated by men over 60, while not a single female ERC laureate is involved in the selection process?” asked Đikić. “This is not a marginal oversight; it is a structural failure.” The ministry of science did not reply to a request for comment. The awards committee is not unusual. For example, a scientific advisory body announced by the ministry of demographics in April comprises 35 men and five women. The board of the Croatian Science Foundation, newly appointed by the parliament, is a little better, with five men and two women, but still unequal. “This is especially significant because such bodies do not merely distribute prestige. They shape research priorities, funding allocation and long-term scientific development,” Marija Lugarić, chair of the parliament’s committee on gender equality, told Science|Business. “Representation here matters not only symbolically, but materially.”Referring to the awards committee and the board of the science foundation, Lugarić says that while both bodies were appointed by parliament, neither met the minimum 40% gender balance threshold that Croatian law and EU guidelines expressly recommend for public bodies.Đikić wants to see EU institutions put pressure on the government to ensure basic standards of fairness, transparency and democratic governance in science policy are met. “Meaningful change will not come without pressure,” he wrote. “It must intensify both within Croatia and at the level of European institutions. Anything less undermines the credibility of Europe’s commitment to excellence and inclusion in science.”Rudež also underlined the importance of talking and writing about this topic, “because public opinion in Croatia does influence changes in the status and visibility of women in science.”The European Commission has not yet responded to a request for comment.Good news from the academyA more positive story came from the Croatian Academy of Sciences and Arts on 21 May, with the announcement of seven new women fellows and five men. This is the first time in the academy’s 165-year history that women have outnumbered men in a new intake.One of the new fellows, two-time ERC grantee Iva Tolić, credits the academy leadership with trying to be more modern and inclusive, representing the whole community better. “The academy is really aware that so far, before this election, there were very few women,” she told Science|Business. “So, they are actively trying to make this more equal.”Related articlesExplained: How the MSCA is close to achieving gender balanceCall for EU to leverage academic freedom in global talent raceRudež is more cautious, noting that despite the academy’s “breakthrough this year [. . .] it is still a predominantly male institution, with only 18% women.”This reflects a wider imbalance in Croatia’s research landscape. “The key levers of power in science are still in the hands of men,” she went on. “For example, all 14 rectors of private and public universities are men.”Similarly, Lugarić says a structural glass ceiling still exists in Croatian science, which is “most visible precisely where power is exercised.”She cites data from the Commission’s She Figures 2024 report, which shows that Croatia ranks second in the EU for gender equality in research and innovation overall, with an equality index of 79.6 out of 100. It is in the top five for women’s career advancement, participation in research; representation across all research sectors and for scientific publications.In stark contrast, it ranks second to last when it comes to women in decision-making positions in science. “This is not a coincidence,” Lugarić says. “It is a structural pattern.”Informal barriersThe persistent under-representation of women in the highest structures of Croatia’s academies, boards, award committees and leadership positions is not down to formal barriers, Lugarić says, but arises from more subtle obstacles such as “informal networks, persistent expectations regarding traditional gender roles and the unequal distribution of care responsibilities.”Tolić would like to see more support for young women in terms of affordable housing and child support, and higher salaries. Currently, she says, salaries in science stay low for the first 10-15 years, while housing and spaces in kindergarten are limited and expensive. “You have to work a lot, you get very little money, so it’s not great to have a family in this situation,” she says.But despite the challenges, Tolić is optimistic, saying that gender equality in research in Croatia is “definitely improving and going in the right direction.” The situation is particularly promising in biology, she adds, where most full professors, heads of department and deans of faculties are women. Lugarić, too, see the glass ceiling “very slowly, cracking,” and cites the academy election as an example that structural change is possible. Yet the situation in the national awards committee is a “stark reminder that without a conscious, systemic commitment to gender balance, progress will remain slow and uneven.”
Inbox: His health will play a big part
It creates competitive imbalance, for sure
Taming UK yields depends on economics not politics
Long-term government borrowing costs above 5% are higher than other developed economies and more sensitive to shocks. It’s tempting to blame political upheaval, but structural factors matter more. The solution is to shrink macroeconomic imbalances and revive capital markets.
Review: FRANKLINLAND Holds the Key to Entertainment at B St. Theatre
Forty years celebrating the iconic B St. Theatre continues with Franklinland, an engaging exploration of power, legacy, and the bonds between father and son. Lloyd Suh’s play about the complexities of Benjamin Franklin has an emotional core that centers on the volatile relationship between the founding father and his son, William. Director Sean Patrick Nill approaches the show with a balance of comedy and sincerity, wasting no time establishing the imbalance between icon and son.
Health expert explains link between women's hormones, stress
Functional medicine practitioner Jennifer Gularson highlights how physiological shifts like menopause can trigger significant stress and hormone imbalances.
Earth's energy imbalance is much more extreme than climate models show — but scientists aren't sure why
For reasons that are still unclear, climate models underestimate the growing gap between the amount of energy Earth receives from the sun and the amount the planet radiates into space.
Physicists just solved a strange fusion mystery that stumped experts
Fusion scientists have solved a long-standing mystery inside tokamaks, the donut-shaped machines designed to harness fusion energy. For years, experiments showed that escaping plasma particles hit one side of the exhaust system far more than the other, but simulations couldn’t explain why. Now, researchers have discovered that the rotation of the plasma itself plays a crucial role—working together with sideways particle drift to create the imbalance.
'Liberation Day' led to trade deals, a 'year of missed opportunities'
New trade deals have sought to address imbalances, but manufacturing jobs are down and businesses are holding back investments.
Live Science Today: Earth hits record energy imbalance, Hawaii floods and NASA prepares for Artemis II launch
Monday, March 23, 2026: Your daily roundup of the biggest science stories making headlines.
Scientists discover ALS protein that links DNA repair to cancer and dementia
A protein tied to ALS and dementia may have a much bigger role in disease than scientists realized. Researchers found that TDP43 controls a key DNA repair process, but when the protein becomes imbalanced, the repair system can spiral out of control, harming neurons and destabilizing DNA. The team also discovered that high levels of the protein are linked to increased mutation rates in cancer. The discovery places TDP43 at the center of both neurodegeneration and cancer biology.
‘We’re in a downward spiral’: Inside the high-stakes battle to reform WorldTour cycling
A confused race calendar and an imbalanced revenue model has led to several attempts to change the sport — could we be nearing a denouement?
Depression may start with an energy problem in brain cells
Researchers have discovered a surprising change in how cells produce energy in people with depression. Brain and blood cells in young adults with major depressive disorder produced more energy molecules at rest but had trouble increasing energy production when needed. Scientists believe this imbalance may contribute to symptoms such as fatigue and low motivation. The finding could help pave the way for earlier diagnosis and more personalized treatments.
Micron’s business is so hot that profits could quadruple in just two years, says this analyst
A massive imbalance in memory supply and demand could benefit Micron through at least 2027, according to a William Blair analyst.
What is Hol+? Dr. Taz’s new holistic health hub explained
Learn how Hol+ blends functional, primary and lifestyle medicine to treat stress, hormone imbalance and metabolism for whole‑body wellness.
Why business must lead the next era of prosperity
Given the stark imbalances between abundance and scarcity and collaboration and isolation, genuine leadership is needed now more than ever to drive prosperity.
New laws to be considered after ‘harrowing stories’ from ex-Vodafone franchisees
Concerns about power imbalance in franchise agreements amid claims over firm’s treatment of small-business owners
The New WHO Pandemic Treaty and Global Health Governance: Incorporating Common but Differentiated Responsibilities into PABS - Georgetown Journal of International Affairs
On May 20, 2025, the World Health Assembly unanimously adopted the World Health Organization (WHO) Pandemic Agreement, an international treaty designed to strengthen pandemic prevention, preparedness, and response. The product of three years of arduous negotiations, the treaty marks a new era of global cooperation in public health. However, core aspects of the agreement remain unresolved—notably the Pathogen Access and Benefit-Sharing (PABS) System, which is intended to ensure equitable access to pandemic-related materials and benefits. To support the successful implementation of the WHO Pandemic Agreement, the principle of “common but differentiated responsibilities” should be formally incorporated into the negotiating agenda of the PABS annex. Introduction For the first time, an international treaty has enshrined the principle of “One Health,” the compelling idea that the health of animals, humans, and the environment all contribute to pandemic risks. SARS (2003), H1N1 (2009–10), Ebola (2014–16), and COVID-19 all emerged through zoonotic spillover from animal hosts—respectively, civets, hogs, and bats. Together, they underscore the need for a coordinated, cross-sectoral approach. The Pandemic Agreement responds to this call, requiring state parties to acknowledge the ecological interplay and commit to a comprehensive “One Health” strategy. Specifically, Article 5 charges governments to address “the drivers of pandemics and the emergence and re-emergence of infectious disease at the human-animal-environment interface,” including wild animal markets, deforestation, and antibiotic overuse. Yet the effectiveness of this “One Health” vision depends equally on the free flow of scientific information and data among countries and institutions. Just as environmental and animal health factors have been neglected in past global frameworks, so too has data sharing been marginalized, despite its centrality to timely detection and response. The Pandemic Agreement takes an important step by requiring governments to enhance data collection and cooperate with the World Health Organization (WHO). However, these provisions will remain aspirational without a robust Pathogen Access and Benefit-Sharing (PABS) annex. The PABS system will determine whether countries and researchers can rapidly exchange pathogen samples and genetic data while ensuring equitable access to resulting research and development, including diagnostics, therapeutics, and vaccines. Without such mechanisms, the treaty’s promise to operationalize “One Health” and strengthen global preparedness will risk becoming largely symbolic, echoing earlier failures to translate shared principles into coordinated action. Equity Concerns When the 2025 Health Assembly adopted the Pandemic Agreement, it left the difficult question of access to pathogens and the sharing of resulting benefits to be addressed in a separate agreement. Negotiations on this separate agreement, PABS, are now underway in Geneva. Yet governments remain divided over fundamental questions of equity between the countries that primarily contribute to the system and those that primarily draw from it—and consequently benefit. For example, wildlife in countries bordering the equator is likely to produce PABS materials, but companies in Europe are likely to use them to develop lucrative products. The most likely contributor countries are likely to be those biodiverse countries around the equator, such as Brazil, the Democratic Republic of the Congo, and Indonesia, where the number of human-mammalian viral host interactions is large. Conversely, countries most likely to benefit from this material are those with the technology, investors, and infrastructure to capitalize on genomic data, such as the United States, EU member states, and Japan. This imbalance reflects a broader pattern seen in prior international frameworks. Now, as in the past, the wealthiest countries in the world (a useful heuristic is membership of the Organisation for Economic Co-operation and Development (OECD)) disproportionately benefit from systems in which pathogens and genomic sequencing data are contributed to a common source. Under the International Agreement on Plant Genetic Resources for Food and Agriculture (the “Plant Treaty” or “Seed Treaty”) and the Pandemic Influenza Preparedness (PIP) Framework, companies from Europe and North America disproportionately withdraw biological samples and data for development into lucrative medical products. Their governments and companies have both statutory and contractual claims to the products that those companies correspondingly produce. PABS appears poised to follow the same pattern. The text calls for strong language on access to pathogens and associated data, but the corresponding benefits that should flow to poorer countries are couched in equivocal or non-binding language. Common but Differentiated Responsibilities To address these inequities, the principle of “common but differentiated responsibilities” should be formally incorporated into the negotiating agenda of the PABS annex. Common but differentiated responsibilities are often a feature of climate change negotiations. The basic principle is that, even though all countries should reduce carbon emissions, governments that became rich and powerful through massive carbon emissions (e.g., France, the United Kingdom, the United States) should have a greater obligation to address the resulting crises. Applied to PABS, it would require that governments hosting and supporting companies developing lucrative products carry greater obligations toward the cost of running the PABS system; share benefits or final medical products; and transfer technology to help countries worldwide develop their own capacities to innovate and manufacture vaccines during an emergency. For example, an annex could mandate that any company based in an OECD country that withdraws PABS material would be obligated to donate the resulting diagnostics, therapeutics, or vaccines to the WHO during a public health emergency or pandemic. Questions remain about how robust those donations would be, but the principle is that they should deliver highly significant lifesaving benefits to be equitably shared. Theoretically, this approach mirrors the PIP Framework, in which companies withdrawing influenza samples are required to pay half of the operating costs. In practice, however, the framework has fallen short. The PIP Framework Secretariat has struggled to secure payments from companies, with companies often disagreeing over how much is owed. Additionally, without another pandemic influenza to test the strength of the agreement during a public health emergency, corporate compliance with sharing mechanisms remains unknown. Even if these limitations did not characterize the PIP Framework, partially paying for operating expenses does not address the inequity in access to genetic data and pathogen samples that left less developed countries last in line for COVID-19 vaccines (and, before them, H1N1). Common but differentiated responsibilities would go further, addressing governments’ legitimate grievances regarding information sharing. It would make withdrawals of PABS material and resulting products more transparent, building trust across the board. Enforcement and Enduring Success A key implication of this approach is that the governing mechanism of the PABS must have real enforcement authority. The WHO Pandemic Agreement delegates its core governance responsibilities to a Conference of the Parties (COP)—a governing body composed of one representative from each participating government, similar to those established under the UN Framework Convention on Climate Change and the WHO Framework Convention on Tobacco Control. The proposed WHO Pandemic Agreement COP is charged with oversight functions but ultimately possesses no real authority to compel a government to take any action it does not wish to take. The text does not give the COP the ability to, for example, sanction a party that does not comply with either textual obligations or PABS provisions. In other words, there are no effective mechanisms in place to ensure compliance. Perhaps just as significant, establishing a meaningful enforcement mechanism within the PABS system would strengthen the WHO’s credibility and its ability to ensure compliance across global health governance. By setting a precedent for accountability, such a mechanism could enhance the organization’s authority not only within the Pandemic Agreement but also in enforcing the revised International Health Regulations and other frameworks for public health emergencies. Conclusion The PABS annex can—and should—be different. It should establish clear responsibilities for funding as well as for sharing the diagnostics, therapeutics, and vaccines that result from contributions to the system. The system, in turn, must include a dedicated body empowered to hold governments and the corporations they sponsor accountable for their responsibilities before, during, and after pandemics. Doing so would restore trust in the broader agreement, which was eroded as commitments were repeatedly diluted while parties scrambled to meet their own self-imposed deadlines during the Pandemic Agreement negotiations. A robust PABS Annex would cement a grand social bargain. Wealthier countries and their corporations would gain unimpeded access to scientific information essential for developing and manufacturing lifesaving medical products. As such, they would stand to gain considerable economic benefit. Yet that privilege must be matched with responsibility. The grand bargain must include not only the right to innovate, but also the duty to ensure that innovation serves all. As medical products are developed and produced through collective contributions, every person must have equal access. All human beings deserve an equitable chance to survive—to save their own life, the lives of their families, and the well-being of their communities. … Sam Halabi, JD, MPhil, is the Bette Jacobs Endowed Professor at Georgetown University’s School of Health and the Director of the Center for Transformational Health Law at Georgetown Law. He serves as the co-lead for the WHO’s Working Group on Regulatory Consideration on AI and Health’s training workstream. He earned his JD from Harvard, his MPhil from Oxford, and undergraduate degrees from Kansas State University. Lawrence Gostin, LLD (Hon.), JD, BA, is University Distinguished Professor and Founding Director and Timothy and Linda O’Neill Professor of the O’Neill Institute for National and Global Health Law. He is the author of Global Health Security: A Blueprint for the Future (Harvard University Press, 2021); Global Health Law (Harvard University Press, 2014); Public Health Law: Power, Duty, Restraint (University of California Press, 3rd ed., 2016); Public Health Law and Ethics: A Reader (University of California Press, 3rd ed., 2018); Law and the Health System (Foundation Press, 2014); Principles of Mental Health Law & Practice (Oxford University Press, 2010). He also directs the WHO Collaborating Center at Georgetown University. Image Credit: United States Mission Geneva, CC BY 2.0, via Wikimedia Commons